Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy.

Published on Jun 1, 2019in Drug Discovery Today6.88
· DOI :10.1016/j.drudis.2019.04.008
Ioannis D Kyrochristos5
Estimated H-index: 5
Demosthenes E Ziogas6
Estimated H-index: 6
Dimitrios H Roukos6
Estimated H-index: 6
(Academy of Athens)
Progress in understanding and overcoming fatal intrinsic and acquired resistance is slow, with only a few exceptions. Despite advances in modern genome and transcriptome analysis, the controversy of the three different theories on drug resistance and tumor progression, namely dynamic intratumor heterogeneity, pre-existing minor genomic clones and tumor ecosystem, is unresolved. Moreover, evidence on transcriptional heterogeneity suggests the necessity of a drug bank for individualized, precise drug-sensitivity prediction. We propose a cancer type- and stage-specific clinicogenomic and tumor ecosystemic concept toward cancer precision medicine, focusing on early therapeutic resistance and relapse.
  • References (89)
  • Citations (3)
📖 Papers frequently viewed together
6 Citations
422 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Last. Dimitrios H Roukos (Academy of Athens)H-Index: 6
view all 3 authors...
: Despite remarkable progress in medium-term overall survival benefit in the adjuvant, neoadjuvant and metastatic settings, with multiple recent targeted drug approvals, acquired resistance, late relapse, and cancer-related death rates remain challenging. Integrated technological systems have been developed to overcome these unmet needs. The characterization of structural and functional noncoding genome elements through next-generation sequencing (NGS) systems, Hi-C and CRISPR/Cas9, as well as c...
6 CitationsSource
#1Nasser K. Altorki (Cornell University)H-Index: 68
#2Geoffrey J. Markowitz (Cornell University)H-Index: 2
Last. Vivek MittalH-Index: 43
view all 8 authors...
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophys...
19 CitationsSource
#1Shu Yi Shen (Princess Margaret Cancer Centre)H-Index: 4
#2Rajat Singhania (Princess Margaret Cancer Centre)H-Index: 8
Last. De Carvalho Dd (U of T: University of Toronto)H-Index: 1
view all 38 authors...
The use of liquid biopsies for cancer detection and management is rapidly gaining prominence1. Current methods for the detection of circulating tumour DNA involve sequencing somatic mutations using cell-free DNA, but the sensitivity of these methods may be low among patients with early-stage cancer given the limited number of recurrent mutations2–5. By contrast, large-scale epigenetic alterations—which are tissue- and cancer-type specific—are not similarly constrained6 and therefore potentially ...
46 CitationsSource
Last. Dimitrios H Roukos (Academy of Athens)H-Index: 6
view all 3 authors...
Despite standardization of multimodal treatment and approval of several targeted drugs for resectable, non-metastatic cancer (M0 patients), intrinsic and acquired resistance and relapse rates remain high, even in early-stage aggressive tumors. Genome analysis could overcome these unmet needs. Our comprehensive review underlines the controversy on stable or spatiotemporally evolving clones as well as promising yet inconclusive data on genome-based biomarkers and drug development. We propose clini...
7 CitationsSource
#1Mihaela Angelova (Paris V: Paris Descartes University)H-Index: 12
#2Bernhard Mlecnik (Paris V: Paris Descartes University)H-Index: 12
Last. Jérôme Galon (Paris V: Paris Descartes University)H-Index: 68
view all 19 authors...
Summary We examined how the immune microenvironment molds tumor evolution at different metastatic organs in a longitudinal dataset of colorectal cancer. Through multiplexed analyses, we showed that clonal evolution patterns during metastatic progression depend on the immune contexture at the metastatic site. Genetic evidence of neoantigen depletion was observed in the sites with high Immunoscore and spatial proximity between Ki67+ tumor cells and CD3+ cells. The immunoedited tumor clones were el...
38 CitationsSource
#1Melissa Haendel (OSU: Oregon State University)H-Index: 42
#2Christopher G. Chute (Johns Hopkins University)H-Index: 64
Last. Peter A. Robinson (UConn: University of Connecticut)H-Index: 52
view all 3 authors...
Ontologies, Phenotypes, and Big Data Data-organizing methods have been in place for centuries, but very large data sets have come into being relatively recently. The authors describe terminologies,...
25 CitationsSource
#1Jin-Ku Lee (SMC: Samsung Medical Center)H-Index: 2
#2Zhaoqi Liu (Columbia University)H-Index: 9
Last. Do-Hyun Nam (SKKU: Sungkyunkwan University)H-Index: 46
view all 54 authors...
Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors to guide optimal patient-tailored therapy. Towards this goal, we have established a compilation of pharmacological landscapes of 462 patient-derived tumor cells (PDCs) across 14 cancer types, together with genomic and transcriptomic profiling in ...
19 CitationsSource
#1Ben O'Leary (ICR: Institute of Cancer Research)H-Index: 8
#2Rosalind J. Cutts (ICR: Institute of Cancer Research)H-Index: 7
Last. Nicholas C. Turner (ICR: Institute of Cancer Research)H-Index: 50
view all 13 authors...
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor–positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples. We conducted paired baseline and end-of-treatment circulating tumor DNA sequencing from 195 patients in the PALOMA-3 randomized phase III trial of palbociclib plus fulvestrant versus placebo plus fulvestrant. We show that clonal evolution occurs frequently...
37 CitationsSource
#1Florian Rambow (Katholieke Universiteit Leuven)H-Index: 17
#2Aljosja Rogiers (Katholieke Universiteit Leuven)H-Index: 9
Last. Jean-Christophe Marine (Katholieke Universiteit Leuven)H-Index: 52
view all 25 authors...
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition. We identified distinct drug-tolerant transcriptional states, varying combinations of which co-occurred within MRDs fro...
45 CitationsSource
#1Uri Ben-David (Broad Institute)H-Index: 24
#2Benjamin Siranosian (Broad Institute)H-Index: 2
Last. Todd R. GolubH-Index: 142
view all 30 authors...
Human cancer cell lines are the workhorse of cancer research. Although cell lines are known to evolve in culture, the extent of the resultant genetic and transcriptional heterogeneity and its functional consequences remain understudied. Here we use genomic analyses of 106 human cell lines grown in two laboratories to show extensive clonal diversity. Further comprehensive genomic characterization of 27 strains of the common breast cancer cell line MCF7 uncovered rapid genetic diversification. Sim...
101 CitationsSource
Cited By3
Last. Dimitrios H Roukos (Academy of Athens)H-Index: 6
view all 6 authors...
Last. Dimitrios H Roukos (Academy of Athens)H-Index: 6
view all 4 authors...
#1Bin Wei (Nanjing Medical University)H-Index: 3
#2Lijuan Xu (Nanjing Medical University)H-Index: 4
Last. Jingjing Wu (Nanjing Medical University)H-Index: 1
view all 5 authors...
Summary Introduction Combination therapy with cisplatin is the conventional first-line treatment in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ubiquitin-specific protease 9X (USP9X) has been shown to be associated with resistance to chemotherapy drugs in several cancers. The purpose of this study was to explore the predictive effects of USP9X on advanced ESCC patients treated with cisplatin-based regimens. Materials and methods The subjects were 69 ad...
#1Rachel Hecht (NIH: National Institutes of Health)H-Index: 1
#2Ming Li (NIH: National Institutes of Health)H-Index: 8
Last. Bradford J. Wood (NIH: National Institutes of Health)H-Index: 65
view all 9 authors...
Objective To develop and assess the accuracy of an augmented reality (AR) needle guidance smartphone application.
1 CitationsSource
Last. Dimitrios H RoukosH-Index: 62
view all 5 authors...
The increasing incidence combined with constant rates of early diagnosis and mortality of colorectal cancer (CRC) over the past decade worldwide, as well as minor overall survival improvements in the industrialized world, suggest the need to shift from conventional research and clinical practice to the innovative development of screening, predictive and therapeutic tools. Explosive integration of next-generation sequencing (NGS) systems into basic, translational and, more recently, basket trials...
4 CitationsSource
Abstract Despite advances in translating conventional research into multi-modal treatment for colorectal cancer (CRC), therapeutic resistance and relapse remain unresolved in advanced resectable and, particularly, non-resectable disease. Genome and transcriptome sequencing and editing technologies, coupled with interaction mapping and machine learning, are transforming biomedical research, representing the most rational hope to overcome unmet research and clinical challenges. Rapid progress in b...
9 CitationsSource